Keyphrases
Tumor
79%
Overall Survival
59%
Chemotherapy
50%
Acute Myeloid Leukemia
49%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
47%
Phase II Study
45%
Multiple Myeloma
41%
Confidence Interval
40%
Breast Cancer
39%
Progression-free Survival
37%
Phase II Trial
36%
Non-small Cell Lung Cancer (NSCLC)
35%
Relapsed or Refractory
31%
Granulocyte Colony-stimulating Factor (G-CSF)
30%
Hematopoietic Stem Cells
29%
T Cells
29%
In Cancer
29%
Clinical Trials
28%
Graft-versus-host Disease (GvHD)
25%
Leukemia
25%
Natural Killer Cells
24%
Rituximab
24%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
22%
Bone Marrow
21%
Hazard Ratio
20%
Human Immunodeficiency Virus Type 1 (HIV-1)
20%
Targeted Therapy
19%
Metastatic Breast Cancer
19%
Non-Hodgkin Lymphoma
19%
Myelodysplastic Syndrome
18%
Adverse Events
18%
Diffuse Large B-cell Lymphoma (DLBCL)
17%
Clinical Outcomes
17%
Mantle Cell Lymphoma
17%
Lung Cancer
17%
Gene Expression
17%
Lymphoma
16%
NCCN Guidelines
16%
Doxorubicin
16%
Follicular Lymphoma
16%
Pancreatic Cancer
15%
Older Adults
15%
Tumor Cells
15%
Overall Response Rate
15%
Triple-negative Breast Cancer
15%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
15%
Cyclophosphamide
15%
Radiation Therapy
14%
High Risk
14%
Macrophages
14%
Complete Response
14%
Oncology
14%
Partial Response
14%
Hematological Malignancies
14%
Median Overall Survival
14%
Gemcitabine
14%
Brentuximab Vedotin
13%
Chimeric Antigen Receptor T Cells (CAR-T)
13%
Lenalidomide
13%
Phase I Study
13%
Placebo
13%
Clear Cell Renal Cell Carcinoma (ccRCC)
13%
Docetaxel
13%
Solid Tumors
12%
Cisplatin
12%
Hematopoietic Cell Transplantation
12%
Programmed Death-ligand 1 (PD-L1)
12%
Melanoma
12%
Hodgkin Lymphoma
12%
Prostate Cancer
12%
Next-generation Sequencing
12%
Disease Progression
12%
Malignancy
12%
Bortezomib
12%
Somatic mutation
12%
Transplantation
12%
Older Patients
12%
Colorectal Cancer
12%
Cancer Types
11%
Human Epidermal Growth Factor Receptor 2 (HER2)
11%
Neutropenia
11%
Pancreatic Ductal Adenocarcinoma
11%
Newly Diagnosed
11%
Paclitaxel
11%
Mouse Model
11%
Response Rate
11%
Tumor Growth
11%
Complete Remission
11%
Apoptosis
11%
Median Progression-free Survival
11%
Glioblastoma
11%
Genetic Modification
11%
Carboplatin
11%
Monotherapy
11%
Randomized Phase II Trial
11%
Metastasis
11%
Relapsed or Refractory multiple Myeloma
10%
Virus
10%
Tumor Microenvironment
10%
Previously Treated
10%
Medicine and Dentistry
Neoplasm
100%
Malignant Neoplasm
80%
Disease
76%
Overall Survival
59%
Chemotherapy
58%
Breast Cancer
56%
Hematopoietic Cell
41%
Multiple Myeloma
37%
Progression Free Survival
34%
Acute Myeloid Leukemia
33%
Clinical Trial
32%
Non Small Cell Lung Cancer
30%
Oncology
29%
Metastatic Carcinoma
25%
T Cell
24%
Immunotherapy
23%
Radiation Therapy
23%
Transplantation
21%
Cell Transplantation
21%
Adverse Event
21%
Arm
20%
Rituximab
19%
Non-Hodgkin Lymphoma
19%
Lung Cancer
19%
Biological Marker
19%
Targeted Therapy
18%
Cancer
18%
Leukemia
18%
Hodgkin's Lymphoma
16%
Diffuse Large B-Cell Lymphoma
15%
Prostate Cancer
15%
Mantle Cell Lymphoma
15%
Melanoma
15%
Hazard Ratio
15%
Clear Cell Renal Cell Carcinoma
14%
Myelodysplastic Syndrome
14%
Pancreas Cancer
14%
Recurrent Disease
14%
Immunity
13%
Tumor Progression
12%
Metastatic Breast Cancer
11%
Pancreas Adenocarcinoma
11%
B Cell
11%
Cancer Cell
11%
Human Immunodeficiency Virus
11%
Doxorubicin
11%
Tumor Cell
11%
Granulocyte Colony Stimulating Factor
10%
Follicular Lymphoma
10%
Phase II Trials
10%
Triple Negative Breast Cancer
10%
Stem Cell
10%
Surgery
10%
Cancer Therapy
10%
Placebo
10%
Connective Tissue Cancer
10%
Hematopoiesis
10%
Cyclophosphamide
10%
Positron Emission Tomography
10%
Solid Malignant Neoplasm
10%
In Vitro
9%
Diagnosis
9%
Cisplatin
9%
Brentuximab Vedotin
9%
Lenalidomide
9%
Quality of Life
9%
Systemic Therapy
9%
Pembrolizumab
9%
Macrophage
9%
Drug Megadose
8%
Paclitaxel
8%
Hematologic Malignancy
8%
Acute Lymphoblastic Leukemia
8%
Stem Cell Transplant
8%
Receptor
8%
Gemcitabine
8%
Hormone Therapy
8%
B-Cell Chronic Lymphocytic Leukemia
8%
Chemoradiotherapy
8%
Small Cell Lung Cancer
8%
Peripheral T-Cell Lymphoma
8%
Neutropenia
8%
Immune Checkpoint Inhibitor
8%
Bortezomib
8%
Soft Tissue Sarcoma
7%
Colorectal Carcinoma
7%
Next Generation Sequencing
7%
Hematopoietic Stem Cell Transplantation
7%
Programmed Cell Death
7%
Glioblastoma
7%
Xenograft
7%
Gene Expression
7%
Infection
7%
Chimeric Antigen Receptor T-Cell
7%
Graft Versus Host Reaction
7%
Epidermal Growth Factor Receptor
7%
Systematic Review
7%
Health Care Cost
7%
Circulating Tumor DNA
7%
Natural Killer Cell
7%